A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Inclusion Criteria: 1. Diagnosed with histologically or cytologically confirmed nonsquamous cell locally advanced (not suitable for definitive therapy) or metastatic non-small-cell lung cancer (NSCLC) (Stage IIIB or IV) NSCLC; and, has received at least 1 prior line of therapy for this disease. 2. A documented epidermal growth factor receptor (EGFR) mutation with in-frame exon 20 insertion, confirmed as follows: * For sites located in the United States (US): assessment must be done by a certified laboratory functioning under the guidelines of the Clinical Laboratory Improvements Amendment (CLIA). * For site located outside of the US: assessment must be done by an accredited local laboratory. Note: A documented EGFR in-frame exon 20 insertion or insertion-duplication includes but is not limited to one of the following: * A763\_Y764insFQEA, * V769\_D770insASV (also referred to as ASV duplication) * D770\_N771insNPG * D770\_N771insSVD (also referred to as SVD duplication) * H773\_V774insNPH (also referred to as NPH duplication), or * Any other in-frame insertion mutation in the exon 20 \[amino acids 739 -823\]. The EGFR exon 20 insertion mutation can be either alone or in combination with other EGFR or HER2 mutations. The reported insertion-duplication can have been detected on either tissue or liquid biopsy using a well-validated test based on either polymerase chain reaction, sequencing or next-generation sequencing (NGS). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 4. Minimum life expectancy of ≥3 months. 5. All toxicities from prior therapy have been resolved to ≤Grade 1, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 or have resolved to baseline, at the time of first dose of TAK-788. Exclusion Criteria: 1. Has been diagnosed with another primary malignancy other than NSCLC, except for the following: 1. Adequately treated non-melanoma skin cancer or cervical cancer in situ. 2. Definitively treated non-metastatic prostate cancer. 3. Non-NSCLC primary malignancies that are definitively relapse-free for ≥3 years. 2. Has unstable brain metastases to include previously untreated intracranial central nervous system (CNS) metastases or previously treated intracranial CNS metastases with radiologically documented new or progressing CNS lesions. \- Brain metastases that are stable do not preclude eligibility if they have been treated with surgery and/or radiation, and have been stable without requiring corticosteroids to control symptoms within 7 days before randomization, and have no evidence of new or enlarging brain metastases. 3. Has a current spinal cord compression (symptomatic or asymptomatic that is detectable by radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic). 4. Currently has or has had a history of interstitial lung disease, to include radiation or drug related pneumonitis that requires/required steroid treatment. 5. Has an ongoing or active infection, to include but not limited to infections requiring intravenous antibiotics or has a known history of HIV. Testing for HIV is not required in the absence of history. Note: Hepatitis B surface antigen-positive participants are allowed to enroll if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is below 1000 copies/mL in the plasma. Patients who are positive for anti-hepatitis C virus antibody can be enrolled but must not have detectable hepatitis C virus (HCV) RNA in the plasma. 6. Have uncontrolled hypertension. Participants with hypertension should be under treatment on study entry to control blood pressure. 7. A prolonged QTcF interval, or is being treated with medications known to be associated with the development of Torsades de Pointes. 8. Has a GI illness or disorder, including but not limited to a history of GI perforation, that could affect oral absorption of TAK-788.